课题基金 / 基金详情

项目摘要

项目成果

PETER Karl SORGER的其他基金

相似基金

相关文献

中文摘要
翻译
行政核心--摘要 癌症前皮肤和血液起源图集中心(Patch Center)将建立 两份癌症前地图集(PCA),结合了来自多个机构的研究人员的专业知识 朗伍德医学区(LMA)、哈佛大学和布罗德研究所。通过利用专业知识和 哈佛医学院系统药理学实验室(LSP)的资源,那里的大多数 补丁中心运营将位于同一地点,管理核心将确保双向交换 与其他PCA/HCA以及人类肿瘤地图集网络的参与者分享研究结果和资源。这个 行政核心将负责为中心的活动提供后勤和组织支持, 协调各机构的工作流程,并与人类肿瘤图集网络(HTAN)互动。 与Htan数据协调中心(Htan-DCC)和NCI(管理核心)密切合作 将确保按照Htan制定的标准收集和共享数据、工具和协议 督导委员会。 目标1将设立一个执行委员会,领导补丁中心及其职能单位 (生物质控、表征和数据分析)和三个小组委员会:(1)质量控制和 保证(QA)小组委员会将负责实施QA/QC流程并遵守 标准作业计划(2)一个里程碑和基准(MB)小组委员会将负责确保及时完成 里程碑和基准以及解决出现的任何问题(Iii)技术开发和 评估(TD)小组委员会将负责评估新技术和新兴技术, 解决现有技术的问题,并与HTAN的其他成员密切合作 技术评估、改进和整合。病理学家桑德罗·桑塔加塔将担任质量 并将其在CLIA实验室操作方面的经验应用于能力和熟练程度 在中心的另一边训练。目标2将制定和维护有效的沟通策略 通过定期会议和电子通信,在补丁中心和Htan中心之间 Slack和Trello等工具;并将确保及时发布Atlas数据,并通过以下方式传输到Htan-DCC 一个API。目标3将对总体和临时中心里程碑进行定期评估,并采取纠正措施 必要时采取行动,包括与NCI沟通任何可能影响整体进度的问题 阿特拉斯建造和释放。
英文摘要
ADMINISTRATIVE CORE – SUMMARY ABSTRACT The Center for Pre-cancer Atlases of Cutaneous and Hematologic Origin (PATCH Center) will construct two pre-cancer atlases (PCAs) by combining the expertise of investigators from multiple institutions in the Longwood Medical Area (LMA), Harvard University and the Broad Institute. By leveraging the expertise and resources of the Laboratory of Systems Pharmacology (LSP) at Harvard Medical School, where the majority of PATCH Center operations will be co-located, the Administrative Core will ensure bi-directional exchange of findings and resources with other PCA/HCAs and with participants in the Human Tumor Atlas Network. The Administrative Core will be responsible for providing logistical and organizational support for Center activities, for coordinating workflows across institutions and for interaction with the Human Tumor Atlas Network (HTAN). Working closely with the HTAN Data Coordinating Center (HTAN-DCC) and the NCI, the Administrative Core will ensure that data, tools and protocols are collected and shared following standards set by the HTAN Steering Committee. Aim 1 will establish an Executive Committee to lead the PATCH Center and its functional units (Biospecimen, Characterization and Data Analysis) and three subcommittees: (i) a Quality Control and Assurance (QA) Subcommittee will be responsible for implementing QA/QC processes and compliance with SOPs (ii) a Milestone and Benchmark (MB) Subcommittee will be responsible for ensuring timely completion of milestones and benchmarks and for addressing any problems that arise (iii) a Technology Development and Evaluation (TD) Subcommittee will be responsible for evaluating new and emerging technologies, troubleshooting problems with existing technologies, and working closely with other members of the HTAN on technology assessment, improvement and integration. Pathologist Sandro Santagata will serve as quality assurance officer and apply his experience in CLIA laboratory operations to competency and proficiency training across the Center. Aim 2 will develop and maintain effective communication strategies within the PATCH Center and between HTAN centers through regular meetings and using electronic communication tools such as Slack and Trello; and will ensure timely release of Atlas data and transfer to the HTAN-DCC via an API. Aim 3 will perform regular evaluation of overall and interim center milestones and take corrective action when required, including communicating to the NCI any problems likely to affect overall progress in Atlas construction and release.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pre-cancer atlases of cutaneous and hematologic origin (PATCH Center)
  • 批准号:
    10818803
  • 项目类别:
  • 资助金额:
    $75.74万
  • 财政年份:
    2023
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs
  • 批准号:
    10405812
  • 项目类别:
  • 资助金额:
    $25.35万
  • 财政年份:
    2021
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
Administrative Core
  • 批准号:
    10494414
  • 项目类别:
  • 资助金额:
    $25.35万
  • 财政年份:
    2021
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs
  • 批准号:
    10343835
  • 项目类别:
  • 资助金额:
    $192.57万
  • 财政年份:
    2018
  • 负责人:
    PETER Karl SORGER
  • 依托单位:
海外基金